Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain- lesioned rats

Psychopharmacology

Volumn 144, Issue 2, 1999, Pages 175-182

  McGaughy, J ^a   Decker, M W ^b   Sarter, M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

192 IgG saporin; ABT 418; Basal forebrain; Methylphenidate; Nicotinic acetylcholine receptor; Rat; Sustained attention

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; IMMUNOGLOBULIN G; METHYLPHENIDATE; NICOTINIC RECEPTOR; SAPORIN;

ACETYLCHOLINE RELEASE; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHOLINERGIC TRANSMISSION; COGNITION; DEAFFERENTATION; DEMENTIA; FOREBRAIN; HYPOTHESIS; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; OLIVARY NUCLEUS; PRIORITY JOURNAL; RAT;

ANIMALS; ATTENTION; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; ISOXAZOLES; MALE; METHYLPHENIDATE; NOOTROPIC AGENTS; PROSENCEPHALON; PYRROLIDINES; RATS; RATS, INBRED F344; RECEPTORS, NICOTINIC;

EID: 0033062919     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050991     Document Type: Article

References (37)

1. 3H]nicotine binding sites. Synapse 21:281-288
2. Arneric SP, Williams M (1994) Nicotinic agonists in Alzheimer's disease: does the molecular diversity of nicotine receptors offer the opportunity for developing CNS-selective cholinergic channel activators? In: Racagni G, Brunello N, Langer SZ (eds) Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunctions. Karger, Basel, pp 58-70
3. Arneric SP, Holladay MW, Sullivan JP (1996) Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease. Exp Opin Invest Drugs 5:79-100
4. Brioni JD, Decker MW, Sullivan JP, Arneric SP (1997) The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv Pharmacol 37:153-214
5. Buccafusco JJ, Jackson WJ, Terry JR AV, Marsh, KC, Decker MW, Arneric SP (1995) Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology 120:256-266
6. Damaj MI, Creasy KR, Welch SP, Rosecrans JA, Aceto MD, Martin BA (1995) Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist. Psychopharmacology 120: 483-490
7. Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Raqdek RJ, Raskiewicz JL, Kang CH, Kim DJB, Giardina WJ, Wasicak JT, Garvey DS, Williams M, Arneric SP (1994) (S-)-3-methyl-5-(1-methyl-2-pyrrolodinyl)isoxazole (ABT-418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther 270: 319-328
8. Evenden JL, Turpin M, Oliver L, Jennings C (1993) Caffeine and nicotine improve visual tracking by rats: a comparison with amphetamine, cocaine and apomorphine. Psychopharmacology 110:169-176
9. Everitt BJ, Robbins TW (1997) Central cholinergic systems and cognition. Annu Rev Psychol 48:649-684
10. Greenwald AG, Gonzales R, Harris RJ, Guthrie D (1996) Effects sizes and P-values: what should be reported and what should be replicated? Psychophysiology 33:175-183
11. Heishman SJ, Taylor RC, Henningfield JE (1994) Nicotine and smoking: a review of effects on human performance. Exp Clin Psychopharmacol 2:345-395
12. Holley LA, Wiley RG, Lappi DA, Sarter M (1994) Cortical cholinergic deafferentation following intracortical infusion of 192 IgG-saporin: a quantitative histochemical study. Brain Res 663:277-286
13. Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108:485-494
14. Jonkman LM, Kemner C, Verbaten MN, Koelega, HS, Camfferman G, v.d. Gagg RJ, Buitelaar JK, van Engeland H (1997) Effects of methylphenidate on event-related potentials and performance of attention-deficit hyperactivity disorder children in auditory and visual selective attention tasks. Biol Psychiatry 41:690-702
15. Keppel G (1991) Design and analysis. Prentice Hall, Englewood Cliffs, N.J.
16. Klein RG (1995) The role of methylphenidate in psychiatry. Arch Gen Psychiatry 52:429-433
17. Koelega HS (1993) Stimulant drugs and vigilance performance: a review. Psychopharmacology 111:1-6
18. McGaughy J, Sarter M (1995) Behavioral vigilance in rats: task validation, and effects of age, amphetamine, and benzodiazepine receptor ligands. Psychopharmacology 117:340-357
19. McGaughy J, Sarter M (1998) Sustained attention performance in rats with intracortical infusions of 192 IgG-saporin-induced cortical cholinergic deafferentation: effects of physostigmine and FG 7142. Behav Neurosci 112:1519-1525
20. McGaughy J, Kaiser T, Sarter M (1996) Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. Behav Neurosci 110:247-265
21. Mirza NR, Stolerman IP (1998) Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology 138:266-274
22. Muir JL, Dunnett SB, Robbins TW, Everitt BJ (1992) Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Psychopharmacology 89:611-622
23. Muir JL, Everitt BJ, Robbins TW (1994) AMPA-induced excitotoxic lesions of the basal forebrain: a significant role of the cortical cholinergic system in attentional function. J Neurosci 14:2313-2326
24. 3 receptor antagonist, ondansetron. Psychopharmacology 118: 82-92
25. Parasuraman R, Warm JS, Dember WN (1987) Vigilance: taxonomy and utility. In: Mark LS, Warm JS, Huston RL (eds) Ergonomics and human factors. Springer, New York, pp 11-32
26. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, Sidney
27. Perry EK, Johnson M, Kerwin JM, Piggott MA, Court JA, Shaw PJ, Ince PG, Brown A, Perry RH (1992) Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging 13:393-400
28. Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, Buccafusco JJ (1998) Central nicotinic receptor agonists ABT-418, ABT-089, and (-) nicotine reduce distractibility in adult monkeys. Psychopharmacology 136:50-58
29. Rusted JM, Graupner L, Tennant A, Warburton DM (1998) Effortful processing is a requirement for nicotine-induced improvements in memory. Psychopharmacology 138:362-368
30. Sarter M, Bruno JP (1994) Cognitive functions of cortical acetylcholine: lessons from studies on transsynaptic modulation of activated efflux. Trends Neurol Sci 17:217-221
31. Sarter M, Bruno JP (1997a) Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Rev 23: 28-46
32. Sarter M, Bruno JP (1997b) Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Behav Brain Res 83:7-15
33. Sarter M, Bruno JP, Himmelheber AM (1997) Cortical acetylcholine and attention: neuropharmacological and cognitive principles directing treatment strategies for cognitive disorders. In Brioni JE, Decker MW (eds) Pharmacological treatment of Alzheimer's disease: molecular and neurobiological foundations. Wiley-Liss, New York, pp 105-128
34. Tago H, Kimura H, Maeda T (1986) Visualization of detailed acetylcholinesterase fiber and neuron staining in rat brain by a sensitive histochemical procedure. J Histochem Cytochem 34: 1431-1438
35. Turchi J, Holley LA, Sarter M (1995) Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats. Psychopharmacology 118:195-205
36. Vasey MW, Thayer JF (1987) The continuing problem of false positives in repeated measures ANOVA in psychophysiology: a mulitvariate solution. Psychophysiology 24:479-486
37. Zar JH (1974) Biostatistical analysis. Prentice Hall, New Jersey